Patient-Reported Disease-Modifying Therapy Adherence in the Clinic: A Reliable Metric?

ABSTRACT:

Background

Adherence to multiple sclerosis (MS) disease-modifying therapy (DMT) is commonly assessed through patient reporting, but patient-reported adherence is rarely studied.

Objective

To determine rates of DMT adherence reported from patient to clinician, reasons for nonadherence, and relationships between adherence and outcomes.

Methods

We identified relapsing-remitting MS patients on DMT for ≥3 months. DMT adherence was defined as taking ≥80% of doses. Linear and logistic regression models were created used to determine the association of baseline adherence with several patient reported outcomes and the timed 25-foot walk at 6 months, 1 year, 2 years, and 3 years after the index visit.

Results

The analysis included 1148 patients, of whom 501 had data at 6

SUBMITTER: Conway DS 

PROVIDER: S-EPMC5971395 | biostudies-literature | 2018 Apr-Jun

REPOSITORIES: biostudies-literature